Phaseline

Targets › SRC

SRC (Proto-oncogene tyrosine-protein kinase Src): drug programs, companies and trials

9 programs from 9 companies in 13 trials: 7 Phase 1, 4 Phase 2, 2 Phase 4; Oncology, Other, Infectious disease; next expected readout Nov 2026.

Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription,…. (UniProt, P12931)

Open in Phaseline: the race on SRC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Skin Center Dermatology GroupTirbanibulin
Tyrosine-protein kinase SRC inhibitor
SRCPhase 4Warts Hand; Cell Carcinoma; Keratinocyte CarcinomaDec 2026
AlmirallTirbanibulin
Tyrosine-protein kinase SRC inhibitor
SRCPhase 4Keratosis, ActinicJul 2027
Amsterdam UMC, location VUmcSaracatinib (AZD0530)
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor
ABL1, SRCPhase 2Fibrodysplasia Ossificans ProgressivaNov 2026
Baylor College of MedicineBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Ruijin HospitalAvastinib
BCR-ABL and SRC family kinase inhibitor
ABL1, SRCPhase 2AMLMar 2030
Nuvectis PharmaNXP900
SRC family kinase inhibitor
SRCPhase 1EGFR Mutation Positive Non-small Cell Lung Cancer; Advanced Solid Tumor; ALK PositiveDec 2026
Turning Point Therapeuticselzovantinib (TPX-0022)
MET/CSF1R/SRC inhibitor
MET, CSF1R, SRCPhase 1Advanced Solid TumorMar 2027
Children's Oncology GroupBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 1Philadelphia Chromosome Positive CMLJul 2028
National Jewish HealthSaracatinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor
ABL1, SRCPhase 1Idiopathic Pulmonary Fibrosis (IPF)–

Conditions

Advanced Solid Tumor (2) EGFR Mutation Positive Non-small Cell Lung Cancer (1) ALK Positive (1) Chronic Myeloid Leukemia (1) AML (1) Fibrodysplasia Ossificans Progressiva (1) Warts Hand (1) Cell Carcinoma (1) Keratinocyte Carcinoma (1) Keratosis, Actinic (1) Philadelphia Chromosome Positive CML (1) Idiopathic Pulmonary Fibrosis (IPF) (1)

Modalities

small molecule (8), other (1)

Companies

Nuvectis Pharma (1) Baylor College of Medicine (1) Turning Point Therapeutics (1) Ruijin Hospital (1) Amsterdam UMC, location VUmc (1) The Skin Center Dermatology Group (1) Almirall (1) Children's Oncology Group (1) National Jewish Health (1)

Related targets

ABL1 (5) HCK (2) LYN (2) BCR (2) MET (1) CSF1R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.